secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001104659-24-031010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q4 net income $0.7M; TAVALISSE sales $25.7M (+17% YoY); acquires GAVRETO rights
--------------------------------------------------------------------------------

- Q4 total revenue $35.8M, TAVALISSE net sales $25.7M (+17% YoY), REZLIDHIA net sales $3.9M (+333% YoY).
- FY 2023 net loss $25.1M ($0.14/sh) vs $58.6M in 2022; revenue $116.9M, TAVALISSE $93.7M (+24% YoY).
- Acquired U.S. rights to GAVRETO (pralsetinib) for RET+ NSCLC/thyroid cancer; expects sales recognition in Q3 2024.
- Q4 TAVALISSE bottles shipped to patients/clinics: 2,463; REZLIDHIA bottles: 278 direct, QoQ growth 47%.
- Cash & short-term investments $56.9M at Dec 31, 2023, vs $58.2M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924031010/0001104659-24-031010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924031010/tm247928d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-031010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer